Detalles de la búsqueda
1.
Recurrent or progressive pediatric brain tumors: population pharmacokinetics and exposure-response analysis of pomalidomide.
Pediatr Res
; 90(4): 832-839, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33469186
2.
Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia.
Pediatr Blood Cancer
; 68(7): e28946, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33694257
3.
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.
Eur J Haematol
; 93(5): 429-38, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24813620
4.
Phase 2 Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors.
Front Oncol
; 11: 660892, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34168987
5.
Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.
Blood Adv
; 5(14): 2901-2908, 2021 07 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-34297046
6.
Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Eur J Cancer
; 136: 116-129, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32688206
7.
Accelerating Pediatric Cancer Drug Development: Challenges and Opportunities for Pediatric Master Protocols.
Ther Innov Regul Sci
; 53(2): 270-278, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29759018
8.
ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children.
Eur J Cancer
; 110: 74-85, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30772656
Resultados
1 -
8
de 8
1
Próxima >
>>